Researchers from the Yong Loo Lin School of Medicine (NUS Medicine) have developed a novel way to engineer yeast ...

Researchers have developed a groundbreaking way to engineer yeast (Saccharomyces cerevisiae ... way for significant advancements in medical treatment while also significantly enhancing the ...

Liraglutide is under clinical development by Novo Nordisk and currently in Phase III for Obesity. According to GlobalData, Phase III drugs for Obesity have a 44% phase transition success rate (PTSR) ...

Treatment for lung cancer varies according to age, type of cancer, extent of disease, tolerance to medication and patient preference. Treatment options include a combination of surgery, radiation, ...

Science Center for Future Foods, Jiangnan University, Wuxi 214122, China Jiangsu Province Basic Research Center for Synthetic Biology, Jiangnan University, Wuxi 214122, China ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

have developed a groundbreaking way to engineer yeast (Saccharomyces cerevisiae) to create microbial communities that can perform complex tasks and self-regulate their composition in response to ...

Researchers from the Yong Loo Lin School of Medicine (NUS Medicine) have developed a groundbreaking way to engineer yeast (Saccharomyces cerevisiae) to create microbial communities that ... paving the ...

In rheumatoid arthritis, which shares some common aetiological pathways and treatments with Crohn disease, treatment goals no longer include symptom control alone, but also alteration of the ...

Probiotic Ingredients Market. The global probiotic ingredients market size is expected to reach a valuation of US$ 9,734.8 ...